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In the last 10 years it has become evident that programmed cell
death (apoptosis) plays an important role in tumorigenesis.
Tumour growth is not only determined by the rate of tumour cell
proliferation but rather by the net result of proliferation and cell
death. Apoptosis is regulated positively and negatively by a wide
range of gene products. bcl-2 was the first protein described that
blocks apoptosis. Besides bcl-2, various other related proteins
have been described like bcl-x and its alternative splicing forms
bcl-xL and bcl-xS (Farrow and Brown, 1996; Yang and Korsmeyer,
1996). Bcl-xL seems to function like bcl-2 and inhibits apoptosis
while bcl-xS seems to promote apoptosis by inhibiting bcl-xL and
bcl-2 function (Minn et al, 1996). Recently, two other cell death
promoting proteins have been discovered, namely bak and bax.
Bak and bax heterodimerize with bcl-2 and bcl-xL and antagonize
the effects of bcl-2 and bcl-xL (Yang and Korsmeyer, 1996). Bax
can homodimerize and promote cell death. The balance between
these proteins by forming bax/bax, bax/bcl-2 or bax/bcl-xL homo-
and heterodimers can be regulated by several factors, including
p53 and c-myc, which may render the cells more susceptible to
apoptosis by lowering the bcl-2/bax ratio (Miyashita et al, 1995).
bcl-2, bcl-x, bak and bax are expressed in normal breast glandular
epithelium and in a subset of breast carcinomas (Doglioni et al,
1994; Krajewski et al, 1994, 1995; Barbareschi et al, 1996; Bargou
et al, 1996; Kapucuoglu et al, 1997; Sierra et al, 1998; Veronese et
al, 1998).
Induction of apoptosis by chemotherapeutics is one of the key
factors in cancer therapy. The resistance of cells to undergo apop-
tosis is in part regulated by the above described gene products. The
number of apoptotic cells and the expression of bcl-2 have been
found to be related in invasive breast cancer (van Slooten et al,
1998). The number of apoptotic cells found in a tumour may there-
fore reflect the inclination of tumour cells to undergo apoptosis.
Various methods have been used to assess the number of apoptotic
cells. Flow cytometry is widely used for assessing the percentage
of apoptotic cells but has the disadvantages of being a non-
morphological method and losing the tumour material after the
measurement. Different staining techniques have been used to
highlight apoptotic cells. Popular methods are terminal transferase
(TdT)-mediated dUTP nick end-labelling (TUNEL) and in situ
end labelling (ISEL) which target fragmented DNA for detection
of apoptotic cells (Weisman et al, 1993). However, the number of
apoptotic cells can also be assessed in haematoxylin and eosin
(H&E)-stained tumour sections. Several studies have used this
method on a range of different tumour types (Leoncini et al, 1993;
Lipponen and Aaltomaa, 1994; Lipponen et al, 1994; Heatley,
1995; Zhang et al, 1999). In a previous study, we showed that
apoptotic cells can be counted in H&E-stained sections with good
inter- and intraobserver reproducibility in invasive breast cancer;
besides, counting in H&E sections needs no additional staining
techniques and is relatively fast. In invasive breast cancer, a high
number of apoptotic cells has been related to a high proliferation
index, poor tumour cell differentiation and an unfavourable prog-
nosis (Lipponen et al, 1994; Berardo et al, 1998; Zhang et al,
1999). As described above, tumour cell behaviour is not only
determined by the rate of proliferation, but also by the rate of cell
death. A combination of measurements of proliferation and apop-
tosis could therefore provide a more realistic prediction of tumour
behaviour. The aim of this study was to evaluate the prognostic
value of the apoptotic index (AI) and its additional prognostic
value to other factors in a series of 172 invasive breast cancers
with long-term follow-up.
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Summary Apoptosis plays an important role in tumorigenesis. Tumour growth is determined by the rate of cell proliferation and cell death. We
counted the number of apoptotic cells in haematoxylin and eosin (H&E)-stained tumour sections in series of 172 grade I and II invasive breast
cancers with long-term follow-up. The number of apoptotic cells in ten high-power fields were converted to the number of apoptotic cells per
mm2 to obtain the apoptotic index (AI). The AI showed a positive correlation to the mitotic activity index (MAI) (P = 0.0001), histological grade
(P < 0.0001) and worse tumour differentiation. Patients with high AI showed shorter overall survival than patients with low AI in the total group
as well as in the lymph node-positive group. Tumour size, MAI, lymph node status and AI were independent prognostic indicators in
multivariate analysis. The AI was shown to be of additional prognostic value to the MAI in the total patients group as well as in the lymph node-
positive group. The correlation between the AI and the MAI points to linked mechanisms of apoptosis and proliferation. Since apoptotic cells
can be counted with good reproducibility in H&E-stained tumour sections, the AI may be used as an additional prognostic indicator in invasive
breast cancer. © 2000 Cancer Research Campaign
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Patients
We used a previously described group of 172 patients with stage I
and II invasive breast cancer (Jannink et al, 1995), diagnosed
between 1971 and 1981 in the Free University Hospital or the
Netherlands Cancer Institute, Amsterdam, The Netherlands. All
patients were treated with radical or modified radical mastectomy
with complete axillary dissection. Postoperative locoregional
radiotherapy was given in all lymph node-positive cases, and none
of the patients received any form of adjuvant systematic therapy.
Median follow-up time was 90 months (range 4–120). Median
follow-up time for the surviving patients was 111 months (range
5–120). The mean age of the patients was 57 years (range 26–92).
Eighty-six patients were diagnosed with positive lymph nodes and
86 patients showed negative lymph nodes. The median tumour
size was 2.5 cm (range 0.2–10.0). Seventy-seven patients had
tumours smaller than 2 cm, 72 patients had tumours 2–5 cm in size
and 23 patients showed a tumour size larger than 5 cm.
Specimen preparation
Fresh operation specimens were cut in slices of approximately 0.5
cm and tumour size was measured. The material was fixed in
neutral 4% buffered formaldehyde. Representative tumour
samples were taken, taking especial care that the periphery of the
tumour was sampled and embedded in paraffin. All lymph nodes
were identified in the axillary dissection specimens and embedded
in paraffin as well. Four-micrometre thick sections were cut from
the paraffin blocks and mounted for routine staining with H&E for
diagnosis, histologic typing according to the WHO criteria,
histologic grading (Elston, 1987), mitoses counting and apoptosis
counting.
Counting of apoptotic cells
In H&E-stained tissue sections, apoptotic cells show retracted and
strongly eosinophilic cytoplasm (Schepop et al, 1996). The nuclear
DNA condenses initially at the nuclear membrane, later forming
clumps, often falling apart into round and homogeneously dark
nuclear fragments. Apoptosis concerns individual cells and does
not provoke an inflammatory reaction. Figure 1 shows examples
of apoptotic cells. Apoptotic cells were counted using a standard
light microscope at a ´ 630 magnification (´ 63 objective, field
diameter 275 mm) according to a strict protocol that was previ-
ously developed (Schepop et al, 1996). In short, the total number
of apoptotic cells was counted in ten fields of vision, systemati-
cally spread over the most poorly differentiated area in the
periphery of the tumour 0.5 ´ 0.5 cm in size. This procedure was
shown to provide good intra- and interobserver reproducibility
(Schepop et al, 1996). All apoptotic counts were expressed per
mm2.
Mitoses counting
Mitotic figures were counted in the same area as described above
in ten consecutive high-power fields at a 400 ´ magnification
using a 40 ´ objective (field diameter 450 mm), starting at the spot
within the measurement field with the highest density of mitotic
figures. The total number of mitotic figures counted in these ten
fields (1.59 mm2) was taken as the mitotic activity index (MAI)
(Baak et al, 1985). The cut off value for the MAI for discrimi-
nating between high and low proliferative tumours was ten mitoses
per ten high power fields, which was shown to be of strong prog-
nostic value in previous studies by us (Baak et al, 1985; Linden et
al, 1987; Uyterlinde et al, 1988; van Diest and Baak, 1992) and
others (Clayton, 1991; Lipponen et al, 1991).
Data analysis
For statistical analysis, grouping was performed using logical
classes for the discrete variables, and for the continuous variables
the median values were used. To assess correlations, confusion
matrices were computed and tested for significance with the c2
test. For the continuous variables, linear regression analysis was
used to assess correlations. For survival analysis, overall survival
time (defined as the time between date of operation and death from
recurrent disease) was used as follow-up parameter. Patients dying
from causes unrelated to breast cancer were censored at the time of
death. Kaplan–Meier curves were plotted, and differences between
the curves were analysed using the log-rank test. Multivariate
analysis was performed with the Cox regression model (enter and
remove limits 0.1) to evaluate additional prognostic value of the
AI to other prognostic variables. All these tests were carried out
with SPSS. P-values below 0.05 were regarded as significant.
RESULTS
The AI showed a non-normal distribution with a range from 1 to 96
and a median value of 10 apoptotic cells per mm2. The AI showed a
positive correlation to the MAI in linear regression analysis (r =
0.36, P < 0.0001). As shown in Table 1, the AI was not associated
lymph node status (P = 0.08). Tumour size showed a weak correla-
tion to the AI with large tumours showing a higher AI than small
tumours (P = 0.049). AI was significantly higher for the ductal and
medullary tumour types compared to the tubular, invasive cribri-
form, mucinous and lobular tumour types (P = 0.003). When
comparing histologic grade and AI, higher histologic grade was
associated with high number of apoptosis (P < 0.0001).
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Figure 1 Examples of apoptotic cells. Early phase apoptosis (A) with
condensed chromatin along the nuclear border and retracted cytoplasm. Late
phase apoptosis (B) showing homogeneously dark single nuclear remnants
and retracted cytoplasm. An apoptotic cell (C) with nuclear fragmentation and
retracted cytoplasmTable 2 shows the results of the univariate survival analysis for
the different variables in the total group of patients. Patients with
high AI showed shorter overall survival than patients with low
apoptotic counts (log-rank 11.6, P = 0.0007, Figure 2). As shown
in Table 3, the AI was also significant in the subgroup of lymph
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Table 1 Correlations between lymph node status, tumour size, histological type and grade and the apoptotic index
Apoptotic index
Variable n Mean Median Range P-value
Lymph node status Negative 86 12.5 9 68 (1–69) 0.081
Positive 86 16.1 12 94 (2–96)
Tumour size < 2.5 cm 80 12.2 9 94 (2–96)  0.049
³ 2.5 cm 92 16.2 12 68 (1–69)
Histologic type Ductal, medullary 132 16.0 12 95 (1–96)  0.003
Others 40 8.9 8 39 (2–41)
Histologic grade I 73 10.2 8 48 (1–49)  < 0.0001
II 61 14.4 12 92 (4–96)
III 38 22.2 8 65 (4–69)
Table 2 Univariate survival analysis results for the total group of patients
Variable Cut-off point n % survival P-value Log-rank
Tumour size < 2.5 cm 80 85 < 0.0001 22.3
³ 2.5 cm 92 48
Histologic type Ductal, medullary 132 66 NS 0.4
Others 40 65
Histologic grade I 73 81 0.0002 16.6
II 61 57
III 38 49
Lymph node status Negative 86 77 0.001 10.7
Positive 86 55
MAI < 10 91 81 < 0.0001 18.7
³ 10 81 50
Apoptotic index < 10 80 78 0.0007 11.6
³ 10 92 55
NS = not significant.
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Figure 2 Survival curves of stage I and II invasive breast cancer patients
with low (< 10) and high (³ 10) AI
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Figure 3 Survival curves of stage I and II invasive breast cancer patients with
low AI and low MAI (n = 58, straight line), low AI and high MAI or high AI and
low MAI (n = 55, dashed line), or high AI and high MAI (n = 59, dotted line)Apoptosis in invasive breast cancer 371
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node positive patients (log-rank 8.1, P = 0.005) but not in lymph
node-negative patients (Table 4). Tumour size, MAI, lymph node
status and AI were shown to be independent prognostic indicators
in multivariate analysis as shown in Table 5. Figure 3 shows the
survival plot for the combination of AI and MAI. Patients with low
AI and low MAI showed the best overall survival whereas patients
with high AI and high MAI showed the shortest overall survival
(log-rank 26.2, P < 0.0001). In the subgroup of lymph node-nega-
tive patients, the AI had no additional value to the MAI. In the
lymph node-positive group, patients with high number of apop-
totic cells and a high MAI showed a significantly shorter overall
survival than the patients with either a low AI or a low MAI (log-
rank 15.7, P = 0.0004).
To compare the number of apoptotic cells with the number of
mitotic figures in the same tumour, we converted the MAI to the
number of mitotic figures per mm2. Eighty-six per cent of tumours
showed a higher number of apoptoses than mitoses per mm2.
DISCUSSION
In accordance with previous studies, also in the present study, the
number of apoptotic cells and the number of mitotic figures
showed a strong correlation (Allan et al, 1991; Lipponen et al,
1994; van Slooten et al, 1997; Berardo et al, 1998, Zhang 1998).
The close relation between high AI and high MAI suggests
common genetic regulators. The c-myc oncogene may be one of
the genes involved in these processes. c-myc can promote cell
proliferation in the presence of growth factors. However, c-myc
induces apoptosis when insulin-like growth factor and platelet-
derived growth factor are not available (Evan et al, 1992, 1996).
Evan et al (1996) proposed that when c-myc is active, there is
simultaneous induction of cell proliferation and apoptosis.
Amplification of c-myc is associated with high proliferation rates
and a poor prognosis in invasive breast cancer (Berns et al, 1992;
Borg et al, 1992). Besides c-myc, other regulators of the cell cycle
are known to play a dual role in the regulation of apoptosis and
proliferation. Cyclin D1 can bind to cyclin-dependent kinases
(cdks) and subsequently phosphorylate retinoblastoma protein
(pRb), thereby releasing the E2F transcription factor, thus acting
as a promoter of cell proliferation. However, neurons in the devel-
oping nervous system undergo apoptosis under the regulation of
cyclin D1 (Kranenburg et al, 1996). In a previous study we found
no correlation between the number of apoptotic cells and the
expression of cyclin D1 in invasive breast cancer (de Jong et al,
1998). Cyclin D1 overexpression was shown to be associated with
Table 3 Univariate survival analysis results for the subgroup of lymph node-positive patients
Variable Cut-off point n % survival P-value Log-rank
Tumour size < 2.5 cm 33 76 0.002 9.8
³ 2.5 cm 53 42
Histologic type Ductal, medullary 70 57 NS 0.0
Others 16 44
Histologic grade I 28 71 0.02 8.0
II 39 51
III 19 35
MAI < 10 42 74 0.003 9.2
³ 10 44 37
Apoptotic index < 10 35 74 0.005 8.1
³ 10 51 41
NS = not significant.
Table 4 Univariate survival analysis results for the subgroup of lymph node-negative patients
Variable Cut-off point n % survival P-value Log-rank
Tumour size < 2.5 cm 47 90 0.003 9.0
³ 2.5 cm 39 55
Histologic type Ductal, medullary 62 77 NS 0.2
Others 24 78
Histologic grade I 45 86 0.03 6.9
II 22 67
III 19 62
MAI < 10 49 86 0.005 8.0
³ 10 37 64
Apoptotic index < 10 45 82 NS 1.8
³ 10 41 72
NS = not significant.
Table 5 Multivariate survival analysis results
Variable s.e.m. P-value Exp(B)
Tumour size 0.0621 0.0001 1.27
MAI 0.0057 0.001 1.02
Lymph node status 0.3113 0.016 0.47
Apoptotic index 0.0078 0.030 1.02
s.e.m. = standard error of the mean, Exp(B) = exponent B.a low number of mitotic figures and low proliferation rate in inva-
sive breast cancer (van Diest et al, 1997). Recent reports showed a
dual role for growth factors and their receptors in induction of
proliferation and apoptosis. The epidermal growth factor receptor
(EGFR) when stimulated with a low dose of EGF can prevent
A431 cells from undergoing programmed cell death. However,
when stimulated with a high dose of EGF, EGF induces inhibition
of cell proliferation and induction of apoptosis (Gulli et al, 1996).
EGF and its receptor may therefore provide a linked role since
increased tyrosine kinase activity can drive two coupled functions,
proliferation and programmed cell death.
We found a high AI to be related to a large tumour size. This is
in line with the study of Zhang et al (1998), but two other studies
found no relation between tumour size and AI (Lipponen et al,
1994; Berardo et al, 1998). A high AI was found in ductal and
medullary tumour types compared to a low AI in the more differ-
entiated tumour types. This is in line with the study of Lipponen et
al (1994). However, the study of Mustonen et al (1997) found no
difference in AI between lobular or ductal breast cancer. As in all
previous published studies the AI in grade 3 tumours was about
twice as high as in grade 1 tumours and grade 2 tumours show AI
in between these two values (Lipponen et al, 1994; Mustonen et al,
1997; van Slooten et al, 1998; Zhang et al, 1998). These results
indicate that poorly differentiated, high-grade tumours with a high
proliferation rate show a high rate of apoptosis. However, the net
rate of proliferation is still so high that they can produce large
tumours as indicated by the relation between AI and tumour size.
The role of p53 in mediating proliferation and apoptosis in inva-
sive breast cancer is still not clear. Wild-type p53 expression can
lead to G1 arrest, thereby inhibiting proliferation. On the other
hand, wt p53 is able to up-regulate bax expression and down-regu-
late bcl-2 expression thereby stimulating apoptosis. In invasive
breast cancer, a large proportion of tumours show strong immuno-
histochemical p53 staining, which is mostly due to a mutation
induced increased half-life of the protein. m-p53 is unable to induce
bax expression and thereby loses its ability to induce apoptosis. In
ovarian cancer cells, p53 mutation induces resistance to cisplatin as
a consequence of loss of the ability of m-p53 to transactivate bax
(Perego et al, 1996). The breast cancer cell line BT474 which has
m-p53 function expresses a high bcl-2/bax ratio and shows resis-
tance to topoisomerase inhibitors treatment (Davis et al, 1998),
underlining the inability of m-p53 to down-regulate bcl-2 expres-
sion and up-regulate bax expression. This study also showed an
association between bcl-2 expression and resistance to apoptosis in
breast cancer cells. In a prospective study on the effect of adjuvant
therapy in metastatic breast cancer, bax expression was correlated
to good treatment response (Sjöström et al, 1998). These studies
underline the potential importance of p53, bcl-2 and bax for
response to adjuvant chemotherapy. In some patients from our
study the number of apoptotic cells seems to be higher than the
number of mitotic figures per mm2, suggesting a negative growth
rate. This paradox can, however, be explained by the persistence of
apoptotic bodies for 30 min to maybe several hours, in contrast to
the relatively rapid completion of mitosis (Staunton and Gaffney,
1998). The actual number of proliferating cells in these tumours is
therefore probably higher than the number of apoptotic cells,
leading to a more plausible positive balance for the net growth of
the tumour. Besides, the length of the mitotic phase may be highly
variable, especially in DNA aneuploid tumours which makes
comparison of the number of apoptotic cells and the number of
mitotic figures more difficult until reliable assessment of the dura-
tion of the apoptotic and mitotic phases becomes possible.
The AI was shown to be of strong prognostic value in this study.
Patients with high AI showed short overall survival compared to
patients with low AI. This is in line with a previous study of
Lipponen et al (1994) who also found high apoptotic counts to be
related to short overall survival. However, Berardo et al, who used
a TUNEL assay to detect apoptotic cells in a series of 979 lymph
node-positive breast cancer patients, found no correlation to
disease-free survival or overall survival when dividing the patients
into low or high rate of apoptosis. When patients were divided into
four separate groups based on the percentage of apoptotic cells,
there was a trend towards worse survival as levels of apoptosis
increased (Berardo et al, 1998). However, the TUNEL technique
can be low in sensitivity and specificity for staining of apoptotic
cells. Some apoptotic cells are not stained while necrotic cells and
inflammatory cells may be falsely positively stained. Besides, the
methodology for scoring the number of apoptotic cells highlighted
by the TUNEL technique is less developed than the ‘H&E’ tech-
nique and requires additional studies. In multivariate analysis we
found the AI to be an independent prognostic indicator with also
additional prognostic value of the MAI. Anti-apoptotic proteins
like bcl-2 and bcl-xL have been related to low rates of cell death
and a favourable prognosis (Sierra et al, 1998; van Slooten et al,
1998) while the pro-apoptotic bax protein showed no relation to
the number of apoptotic cells or prognosis in invasive breast
cancer in most studies (Sierra et al, 1998; van Slooten et al, 1998;
Veronese et al, 1998). The number of apoptotic cells may therefore
reflect the net result of the pro- and anti-apoptotic stimuli,
providing an easy to use tool to assess the capability of tumours to
undergo programmed cell death. Since counting of apoptotic
bodies can be performed with good reproducibility (Schepop et al,
1996), it is a promising novel prognostic indicator in invasive
breast cancer with additional prognostic value to tumour size,
lymph node status and mitotic index. The AI deserves to be
studied prospectively, especially with regard to response to adju-
vant therapy.
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